CF PHARMTECH (02652) Included in Shanghai-HK and Shenzhen-HK Stock Connect

Bulletin Express03-08

CF PHARMTECH (02652) announced that its H shares have been officially included in the list of eligible securities under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, effective March 9, 2026. According to the announcement, qualifying mainland Chinese investors will be able to trade the company’s H shares through these channels once the inclusion takes effect.

The announcement highlights expectations that this development may help increase the company’s shareholder base and boost trading liquidity of its H shares. CF PHARMTECH, Inc. is primarily engaged in inhalation drug delivery technology, focusing on complex inhalation formulations and integrated capabilities in device engineering, precision drug delivery, and global regulatory filing.

The company stated that it is advancing its innovative pipeline in China, the United States, and Europe, emphasizing efforts in respiratory and nasal disease treatments, as well as strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections, and potential nose-to-brain delivery for central nervous system disorders. It also noted a developing commercialization network in China, along with globally compliant manufacturing systems, to support its long-term goal of becoming an international pharmaceutical enterprise.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164337640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-08 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164337640","market":"hk","top_or_hot":-1,"title":"CF PHARMTECH (02652) Included in Shanghai-HK and Shenzhen-HK Stock Connect","media":"Bulletin Express","content":"<p>CF PHARMTECH (02652) announced that its H shares have been officially included in the list of eligible securities under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, effective March 9, 2026. According to the announcement, qualifying mainland Chinese investors will be able to trade the company’s H shares through these channels once the inclusion takes effect.</p>\n<p>The announcement highlights expectations that this development may help increase the company’s shareholder base and boost trading liquidity of its H shares. CF PHARMTECH, Inc. is primarily engaged in inhalation drug delivery technology, focusing on complex inhalation formulations and integrated capabilities in device engineering, precision drug delivery, and global regulatory filing.</p>\n<p>The company stated that it is advancing its innovative pipeline in China, the United States, and Europe, emphasizing efforts in respiratory and nasal disease treatments, as well as strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections, and potential nose-to-brain delivery for central nervous system disorders. It also noted a developing commercialization network in China, along with globally compliant manufacturing systems, to support its long-term goal of becoming an international pharmaceutical enterprise.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PHARMTECH (02652) Included in Shanghai-HK and Shenzhen-HK Stock Connect</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PHARMTECH (02652) Included in Shanghai-HK and Shenzhen-HK Stock Connect\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-08 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PHARMTECH (02652) announced that its H shares have been officially included in the list of eligible securities under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, effective March 9, 2026. According to the announcement, qualifying mainland Chinese investors will be able to trade the company’s H shares through these channels once the inclusion takes effect.</p>\n<p>The announcement highlights expectations that this development may help increase the company’s shareholder base and boost trading liquidity of its H shares. CF PHARMTECH, Inc. is primarily engaged in inhalation drug delivery technology, focusing on complex inhalation formulations and integrated capabilities in device engineering, precision drug delivery, and global regulatory filing.</p>\n<p>The company stated that it is advancing its innovative pipeline in China, the United States, and Europe, emphasizing efforts in respiratory and nasal disease treatments, as well as strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections, and potential nose-to-brain delivery for central nervous system disorders. It also noted a developing commercialization network in China, along with globally compliant manufacturing systems, to support its long-term goal of becoming an international pharmaceutical enterprise.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1164337640","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164337640","pubTimestamp":1772966562,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PHARMTECH (02652) announced that its H shares have been officially included in the list of eligible securities under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PHARMTECH(02652)纳入沪港深港通","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PHARMTECH (02652) announced that its H shares have been officially included in the list of eligible securities under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, effective March 9, 2026. According to the announcement, qualifying mainland Chinese investors will be able to trade the company’s H shares through these channels once the inclusion takes effect.\nThe announcement highlights expectations that this development may help increase the company’s shareholder base and boost trading liquidity of its H shares. CF PHARMTECH, Inc. is primarily engaged in inhalation drug delivery technology, focusing on complex inhalation formulations and integrated capabilities in device engineering, precision drug delivery, and global regulatory filing.\nThe company stated that it is advancing its innovative pipeline in China, the United States, and Europe, emphasizing efforts in respiratory and nasal disease treatments, as well as strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections, and potential nose-to-brain delivery for central nervous system disorders. It also noted a developing commercialization network in China, along with globally compliant manufacturing systems, to support its long-term goal of becoming an international pharmaceutical enterprise.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164337640","isCrawlerRequest":true}